Yakang Biotech announced that in the first half of 2026, it achieved operating income of 460 million yuan, an increase of 22.61% year on year; net profit attributable to shareholders of listed companies was 111 million yuan, an increase of 56.28% year on year; net profit after deducting non-recurring profit and loss was 959.17,600 yuan, an increase of 52.43% year on year. The company plans to distribute a cash dividend of 1.30 yuan for every 10 shares to all shareholders based on the total share capital of the equity distribution date after deducting the shares in the special account for the repurchase. The total amount is estimated to be 53.193 million yuan, accounting for 48.00% of the net profit due to the current period. No bonus shares or the share capital will be transferred from the capital reserve fund. The plan still needs to be reviewed and approved by the shareholders' meeting.

Yakang Biotech announced that in the first half of 2026, it achieved operating income of 460 million yuan, an increase of 22.61% year on year; net profit attributable to shareholders of listed companies was 111 million yuan, an increase of 56.28% year on year; net profit after deducting non-recurring profit and loss was 959.17,600 yuan, an increase of 52.43% year on year. The company plans to distribute a cash dividend of 1.30 yuan for every 10 shares to all shareholders based on the total share capital of the equity distribution date after deducting the shares in the special account for the repurchase. The total amount is estimated to be 53.193 million yuan, accounting for 48.00% of the net profit due to the current period. No bonus shares or the share capital will be transferred from the capital reserve fund. The plan still needs to be reviewed and approved by the shareholders' meeting.